Premium
Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide
Author(s) -
Rayburg Melissa,
Towbin Alexander,
Yin Hong,
Maugans Todd,
Maurer Barry,
Nagarajan Rajaram,
Weiss Brian
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22200
Subject(s) - langerhans cell histiocytosis , medicine , fenretinide , neuroblastoma , blood cancer , histiocytosis , lesion , pathogenesis , pathology , cancer , dermatology , retinoid , disease , retinoic acid , biochemistry , chemistry , genetics , biology , gene , cell culture
Langerhans cell histiocytosis (LCH) has previously been reported in association with other malignancies. The pathogenesis of LCH and its relationship to other malignancies is poorly understood. We present a novel case of a child who developed an LCH bone lesion while receiving a Phase I protocol therapy with oral fenretinide/Lym‐X‐Sorb (4‐HPR/LXS) powder for neuroblastoma. Pediatr Blood Cancer 2009;53:1111–1113. © 2009 Wiley‐Liss, Inc.